title: Relation between course of disease in type 1 diabetes and islet cell antibodies.
abstract: The aim of this study was to estimate the possibility of predicting the course of type 1 diabetes. We analyzed the importance of islet cell antibody levels and residual beta cell function in 46 newly diagnosed patients with diabetes. Islet cell antibodies (ICAs; Juvenile Diabetes Foundation [JDF] units) were determined at the time of diagnosis by the indirect immunofluorescent method. beta cell function was estimated by C peptide levels (nmol/L) before and after glucagon stimulation at the time of clinical remission. Of the 46 patients, 13 were ICA negative (group A). Among ICA-positive patients, ICAs were < 20 JDF units (group B) in 15, between 20 and 80 JDF in 9 (group C), and > 80 JDF in 9 (group D). In group A, 9 patients had clinical remission for 7.5 +/- 1.7 months. Their basal C peptide level was 0.26 +/- 0.05 nmol/L and it increased after stimulation to 44.5 +/- 2.5%. Ten patients in group B had remission for 6.2 +/- 1.5 months. Their basal C peptide levels (0.28 +/- 0.07 nmol/L) were similarly increased after stimulation (47.5 +/- 2.5%). In group C, all patients had remission and it was of the longest duration (14.7 +/- 1.5 months). They had the highest basal C peptide levels (0.45 +/- 0.12 nmol/L) with increases to 57.5 +/- 3.5%. Seven patients in group D with ICA levels > 80 JDF had a short remission (3.2 +/- 1.2 months) despite good basal C peptide levels (0.42 +/- 0.05 nmol/L) and excellent increases after stimulation (92.5%). Our results suggest that moderate levels of ICA are associated with good residual beta cell function and longer remission. Very high ICA levels (> 80 JDF) at the time of diagnosis despite better beta cell function are associated with short clinical remission. Therefore, high ICA levels could be a marker of strong autoimmune reaction and accelerated depletion of beta cell function.
authors.affiliation: Institute for Endocrinology, Diabetes and Metabolic Disease, Clinical Center of Serbia, School of Medicine, Belgrade University, 11000 Belgrade, Yugoslavia. hose@EUnet.yu
authors.forename: M
authors.initials: M
authors.lastname: Zamaklar
authors.forename: A
authors.initials: A
authors.lastname: Jotic
authors.forename: N
authors.initials: N
authors.lastname: Lalic
authors.forename: K
authors.initials: K
authors.lastname: Lalic
authors.forename: N
authors.initials: N
authors.lastname: Rajkovic
authors.forename: T
authors.initials: T
authors.lastname: Milicic
mesh_terms: D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000276:immunology*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000503:physiopathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007515:Islets of Langerhans / Q000276:immunology*; D008297:Male
chemical_list: D001323:Autoantibodies; C024211:islet cell antibody